Acute myeloid leukemia (AML) cells are malignant counterparts of normal myeloid pathway progenitors. Myeloid progenitors differentiate into professional antigen presenting cells (APC) under the essential influence of GM-CSF along with additional cytokines. Twelve cases of human AML were tested for ability to be differentiated toward a professional APC phenotype in short-term culture with addition of GM-CSF and the following recombinant proteins: TNF␣, IL-4, CD40 ligand, Flt3 ligand and SCF. Significant upregulation of CD80 (B7-1) and enhancement of alloantigen presentation was seen with the addition of GM-CSF and TNF␣ alone or with additional cytokines. The combination of GM-CSF and TNF␣, either alone or in combination with an additional cytokine, resulted in enhancing alloantigen presentation by at least two-fold over the media control group in 10/12 patients studied, and resulted in CD80 expression of greater than 15% in 11/12 patients studied. In AML cultures with GM-CSF and TNF␣, coexpression of CD80 and either CD34 or an aberrant surface marker (CD56) was seen. In one case, sorted CD80
Introduction
Dendritic cells are potent professional antigen presenting cells found in small numbers in the blood, skin, and lymphoid organs. 1 When derived from a bone marrow CD34 + myeloid progenitor, dendritic cells develop under the essential influence of GM-CSF and TNF␣, 2, 3 with an intermediate that is shared with monocyte development. 4 Additionally, dendritic cells can develop from a peripheral blood CD14 + monocyte population under the influence of GM-CSF and IL-4. 5, 6 The dendritic cells developing from these culture conditions are characterized by a characteristic morphology and upregulation of HLA-DR, the costimulatory molecules CD80 and CD86, and the relatively dendritic cell restricted markers CD1a and CD83. 7 Cultured dendritic cells are also extremely potent in presenting antigen and stimulating naive T cells, including allogeneic T cells in a MLC, in part due to the high expression of CD80 and CD86. 8 AML cells represent a malignant population of myeloid progenitor cells arrested along different pathways of normal myeloid development. The current French-American-British (FAB) classification schema reflects the organization of clinical cases of AML into groups corresponding to different points in myeloid differentiation. 9 Despite an apparent arrest at a specific stage of differentiation, some AML cells can be induced
Correspondence: MW Boyer, Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA Received 4 April 1999; accepted 22 October 1999 to undergo lineage-specific maturation by in vitro culture with cytokines such as GM-CSF, IL-3 and IL-6. 10 Since the majority of AML express CD34 and appear arrested at a relatively early stage of myeloid development, we reasoned that they might be induced to differentiate at least partly into a dendritic cell phenotype by in vitro culture with GM-CSF and TNF␣. Alternatively, CD14
+ AML cells may require additional IL-4 in order to differentiate toward a dendritic cell phenotype. Therefore, 12 cases of human AML were studied by in vitro culture with GM-CSF and TNF␣ (with or without additional IL-4) with respect to change in the surface phenotype and ability to stimulate allogeneic T cells in MLC. Additionally, CD40 ligand, 11 stem cell factor (SCF), 12 and Flt3 ligand 13 were studied because of reported activity in the development or activation of dendritic cells. Substantial activity of GM-CSF in combination with TNF␣ was observed in cultures of AML with regard to upregulation of the costimulatory molecule CD80 and alloantigen presentation. Additional Flt3 ligand, CD40 ligand, and IL-4 all had activity with regard to either CD80 upregulation or alloantigen presentation. These results are discussed with regard to possible immunotherapeutic application.
Materials and methods

Human AML samples
Human AML samples were obtained by bone marrow aspiration or central venous blood draw from patients on both the Adult and Pediatric Leukemia Services at Emory University according to institutional guidelines, with informed consent. Samples were collected with preservative-free heparin or acidcitrate anti-coagulants and subjected to Histopaque-1077 (Sigma, St Louis, MO, USA) density gradient separation. Aliquots were stored frozen in 10% DMSO, 40% RPMI (Mediatech, Herndon, VA, USA), and 50% human AB-pooled, heat inactivated serum (Atlanta Biologicals, Norcross, GA, USA).
Cell culture
Cells were suspended at 10 6 cells/ml in complete media consisting of: RPMI 1640, 10% human AB-pooled, heat inactivated serum, 25 mM hepes, glutamax (1%), pen/strep antibiotics (1%), and 50 mol 2-ME (all Gibco/BRL Life Technologies, Frederick, MD, USA). The following recombinant human proteins were aliquoted and stored at −80°C until added to cultures (final concentrations): GM-CSF (100 ng/ml), Flt3 ligand (10 ng/ml), and CD40 ligand (100 ng/ml) were kind gifts of Immunex Corp, Seattle, WA, USA; SCF (10 ng/ml) a kind gift of Amgen Corp, Thousand Oaks, CA, USA; TNF␣ (10 ng/ml) and IL-4 (50 ng/ml) (both Peprotech, Rocky Hill, NJ, USA). Cultures were performed in 6-well plates incubated in 5% CO 2 at 37°C for 5 days. At the end of the culture period most cultures were subjected to Histopaque-1077 (Sigma) density gradient separation to bring the cell viability up to at least 85%. In all cases, cultured cells were washed at least two times prior to use in the MLC. 
Mixed lymphocyte cultures (MLC)
Random donor
Flow cytometry
Cells were stained with FITC or PE conjugated monoclonal antibodies (clone designation) against CD13 (SJ1D1), CD83 (HB15a) (both from Immunotech, Marseille, France), CD14 (M5E2), CD33 (WM53), CD56 (B159), CD1a (MT102), CD80 (BB1), CD86 (FUN-1), CD40 (5C3), HLA-DR (G46-6) (all from PharMingen, San Diego, CA, USA), CD80 (L307.4), CD34 (8G12), CD15 (MMA), and CD117 (104D2) (Becton Dickinson, San Jose, CA, USA). Isotype matched controls (mIgG1, mIgG2a/b, and mIgM, PharMingen) were used to determine background staining. Stained cells were then washed with PBS/1% BSA/0.02% Na azide solution, and then stained with propidium iodide (PI) to exclude dead cells. Data were acquired using a BD FACScan (Becton Dickinson), and analyzed using the Paint-a-Gate Pro software (Becton Dickinson).
FISH analysis
Karyotype analysis was performed on uncultured thawed cells, and on cells cultured with GM-CSF/IL-4 from a patient previously identified with a 47,XX,inv(16)(p13q22), +22 karyotype in all bone marrow metaphases. Utilizing routine cytogenetic methods involving GTG banding, metaphases were analyzed and chromosome abnormalities described in accordance with the ISCN nomenclature. Conventional interphase FISH was performed using the bcr/abl translocation probe (Oncor, Gaithersburg, MD, USA). A total of 200 cells were scored. The number of positive bcr signals per cell was used to determine the number of copies of chromosome 22. Denaturization and hybridization were carried out according to the manufacturer's directions. 
Statistics
The paired two-way Student's t-test was used for statistical analysis. Experimental groups of AML cultures with cytokines were compared individually to the media control group. A P value of Ͻ0.05 was considered statistically significant.
Results
Characteristics of AML studied
The FAB type, source of cells, and immunophenotype of all 12 patient samples studied are outlined in Table 1 . Nine samples were from the initial diagnostic bone marrow aspirate, while three samples were peripheral blood samples taken from patients with high WBC (Ͼ100 000/l). All samples except one (patient No. 8) represented Ͼ85% blasts. The median CD33 expression was 88%; 8/12 were CD34 + , 9/12 were CD117
+ (c-kit/SCF receptor) and 11/12 HLA-DR + based on minimum 10% expression. As expected there was no detectable expression of the dendritic cell markers CD1a or CD83. There was also no expression of CD80 and only one case expressed CD40. Interestingly, 8/12 cases demonstrated some expression of CD86 with a median of 19%.
Effects of GM-CSF and TNF␣, IL-4, CD40L, SCF, and Flt3L on alloantigen presentation and expression of costimulatory molecules by AML
Uncultured AML cells were poor stimulators of allogeneic T cells in a MLC as seen in Figure 1a . Cells cultured in media alone were no different than thawed cells and those cultured in GM-CSF were only slightly better stimulators. AML cells cultured in GM + TNF␣ yielded a cell population that was significantly better at stimulating allogeneic T cells (P = 0.002 compared to the media group). The addition of Flt3 ligand or CD40 ligand to GM-CSF + TNF␣ also yielded statistically enhanced alloantigen presentation (P = 0.02 and P = 0.03, respectively). In 10 out of 12 cases studied, the combination of GM-CSF + TNF␣ ± additional cytokines enhanced alloantigen presentation at least two-fold compared to the media control group.
Expression of CD86 was already present before culture at a low level, and was not altered by culture in media alone or any cytokine combination except GM-CSF + TNF␣ + IL-4 (mean expression of 34.8% vs media control group 22.6%, P = 0.03; data not shown). The most dramatic alteration after culture in GM-CSF + other cytokines was upregulation of CD80 expression (Figure 1b ) from a mean of 0.6% on uncultured cells to as high as 80% in one individual case. The combinations of GM-CSF + TNF␣ + CD40L or GM-CSF + TNF␣ + IL-4 gave the most statistically significant upregulation of CD80 compared to the media control group (P = 0.006 and P = 0.008, respectively). Culture in the combination of GM-CSF + TNF␣ ± additional cytokines resulted in expression of CD80 of Ͼ15% in 11/12, Ͼ25% in 7/12, and Ͼ50% in 4/12 cases. Interestingly, HLA-DR expression was not increased with culture in any cytokine combination (data not shown). + AML, optimal CD80 and CD86 expression required IL-4 in culture in 3/5 and 2/5 cases, respectively. Additionally, it was hypothesized that either SCF or Flt3 ligand might enhance yields of cultured AML blasts, but there was no effect from the addition of SCF or Flt3L on cell yields of cells cultured with GM-CSF and TNF␣ (data not shown).
Phenotype and morphology of cultured AML cells
Some of the cultures which GM-CSF + TNF␣ ± other cytokines yielded small to medium clusters of cells reminiscent of dendritic cell cultures from normal CD34 + progenitors. Several cultures contained cells with dendritic-like morphology, and, uniformly, cells expressing CD80 after in vitro culture displayed high side and forward scatter properties characteristic of dendritic cells (data not shown). In 10 cases data on CD1a and CD83 expression after culture with GM-CSF ± TNF␣, IL-4 and CD40L were available and revealed upregulated CD1a in 7/10 and CD83 in 4/10 cases. Every case of upregulated CD83 expression included CD40L in the culture (Figure 2 ).
Figure 2
Combination of GM-CSF + TNF␣ + CD40L upregulates CD83 expression on AML. AML cells from patient 8 were cultured for 5 days with the indicated cytokines and analyzed for CD80 and CD83 coexpression by FACS.
Retention of stem cell markers, aberrant markers, and cytogenetic markers in AML cells expressing CD80 after cytokine culture
To demonstrate that cells with characteristics of a professional APC obtained from cultures of AML cells were in fact derived from the leukemic clone, we focused upon CD80-positive cells since expression is strictly limited to professional antigen presenting cells, ie activated B cells, activated monocytes and dendritic cells. In one case there was concomitant high expression of both CD34 and aberrant expression of CD56 (patient 4 in Table 1 ) which were also evident on the CD80-positive cells obtained after culture in GM-CSF + TNF␣ ( Figure  3 ). In another case CD34 expression was detected along with a cytogenetic marker amenable to detection by FISH (trisomy 22; patient number 9 in Table 1 ). CD80( + ) cells were sorted by flow cytometry after culture in GM-CSF and IL-4 for 5 days. The CD80 sorted cells were compared to uncultured and cultured but unselected cells in MLC, and analyzed by FISH for trisomy 22. As seen in Figure 4 , the CD80 sorted cells retained the trisomy 22 cytogenetic abnormality, and were enhanced stimulators of allogeneic T cells in MLC. Furthermore, phenotypic analysis revealed coexpression of CD34 by the CD80 sorted cells ( Figure 5 ). Together, these data provide evidence that the CD80-positive cells with enhanced antigen presenting capability are derived directly from AML cells after short-term culture in cytokines.
Discussion
The data presented demonstrate that AML cells are poor stimulators of allogeneic T cells despite expression of HLA-DR. Others have also documented poor alloantigen presentation by human AML blasts, with the degree of alloreactive T cell stimulation dependent upon the level of HLA-DR expression.
14 The data presented demonstrate that short-term Leukemia culture with GM-CSF in combination with TNF␣, IL-4 or CD40 ligand significantly enhances alloantigen presentation by a factor of approximately five-fold. The enhanced MLC stimulation was related primarily to upregulation of CD80 since neither CD86 (with exception of the GM-CSF + TNF␣ + IL-4 group) nor HLA-DR expression was enhanced after in vitro culture. Blockade of costimulation by CD80 and CD86 in a standard MLC results in substantial (greater than 50%) inhibition of T cell proliferation, which would correlate with our findings of markedly enhanced alloantigen presentation secondary to upregulated CD80 expression. 15 In other studies of human AML, only one of 54 cases was found to express CD80 while 15 of 54 expressed CD86 16 supporting the significance of upregulated CD80 in our study.
A case of AML, FAB M2, was described in which in vitro culture with GM-CSF and TNF␣ led to the appearance of dendritic cell-like colonies and cells with enhanced alloantigen presentation. 17 Subsequent studies have examined the extent to which human AML blasts could be induced to express costimulatory molecules and enhance alloantigen presentation to T cells. One study examined 20 patient samples of primarily FAB M4 and M5 AML, and data were reported for response to IFN␥ and CD40 ligand in vitro. IFN␥ induced significant upregulation of both CD80 and CD86, while incubation on CD40 ligand transfected fibroblasts induced significant upregulation of only CD86. 18 Neither stimulation conditions enhanced the ability of the AML blasts to present alloantigen to T cells in a MLC. In a separate report of five AML patients, culture in GM-CSF, IL-4 and TNF␣ resulted in AML cells with morphologic features suggestive of dendritic cells and expression of CD80 in four out of the five cases studied. 19 In a subsequent report by the same group of investigators, data regarding enhanced MLC reactivity of AML blasts incubated in GM-CSF, IL-4 and either TNF␣ or CD40 ligand in five patient samples suggested that the combination of GM-CSF + IL-4 + CD40 ligand resulted in the most consistently enhanced alloantigen presentation. 20 The last two reports consisted of patients with varying FAB subtypes. These published data along with the data presented here suggest the phenomenon of enhanced APC function by AML after culture in specific cytokines is not limited to specific cases of AML but is generalizable to the majority of AML of differing FAB subtypes. In terms of the particular cytokine necessary to induce this phenomenon in human AML, our data clearly show GM-CSF in combination with additional cytokines is essential. Based upon upregulated CD80 expression it would appear that TNF␣ with CD40 ligand or IL-4 would be the most potent cytokine combination.
Two lines of evidence suggest that the enhanced antigen presenting cells expressing CD80 were derived directly from the cultured AML cells and not a minor contaminating population. First, the percentage of CD80-positive dendritic cells obtained in a short (6 day) culture of CD34 purified cells with GM-CSF, TNF␣ and SCF is only about 2%, 4 much less than the mean level of expression of CD80 seen in the cultured AML cells presented in this report. It would seem highly unlikely then that a minor population of normal CD34 + progenitors could account for the majority of the enhanced APC developing in the cultures of AML blasts. Of more concern would be contaminating normal CD14
+ cells which could give rise to large numbers of dendritic cells after short-term culture in GM-CSF and IL-4. 5, 6 However, evidence is provided that clearly demonstrates in one case of CD14 + AML that the cells with a CD80 phenotype obtained after in vitro culture with GM-CSF and IL-4 are derived from AML cells directly AML blasts cultured in GM-CSF + TNF␣ display coexpression of CD80 with both CD34 and an aberrant surface marker (CD56). AML cells from patient 4 were cultured for 5 days with GM-CSF + TNF␣ and analyzed for CD80, CD34 and CD56 expression by FACS.
Figure 4
Retention of cytogenetic abnormalities in cultured AML cells selected for CD80 expression. AML cells from patient 9 were cultured for 5 days with GM-CSF/IL-4 and then sorted for CD80(+) cells, utilized in an MLC, and studied by FISH for presence of trisomy 22.
Figure 5
Coexpression of CD34 and CD80 on AML cells cultured in GM-CSF/IL-4. AML cells, either freshly thawed, cultured in GM-CSF/IL-4 for 5 days, or cultured and sorted by CD80 positivity were costained with CD80 and CD34 and analyzed by FACS. (Figures 4 and 5 ). This conclusion is based on demonstrating in the CD80 + cells a clonotypic cytogenetic abnormality present in the original cytogenetic analysis of uncultured leukemia. Furthermore, a proportion of the CD80 + cells still retained the stem cell surface antigen CD34, present in the uncultured leukemia. A further example of coexpression of CD34 and CD80, as well as an aberrantly expressed nonmyeloid surface marker (CD56) and CD80 is provided in Figure 3 . While CD86 and CD34 coexpression has been described in normal bone marrow progenitors, 21 CD80 and CD34 coexpression has not been previously described. These data are compelling evidence that short-term culture of AML blasts in GM-CSF + TNF␣ ± CD40 ligand or IL-4 directly upregulates CD80 expression by the leukemia blasts and enhances alloantigen presentation by the blast population.
We have previously described the effects of genetically modifying murine AML cells to express the costimulatory molecules B7-1 (CD80) and B7-2 (CD86).
22 B7 expressing murine AML cells but not unmodified AML cells were capable of stimulating and expanding an autologous leukemia-specific cytotoxic T lymphocyte (CTL) clone. This CTL clone was shown to induce a potent graft-versus-leukemia effect when adoptively transferred to mice in an autologous BMT model of AML. Other investigators have studied B7 transduced murine leukemia cells as cellular vaccines and concluded that expression of B7-1 in particular was effective in enhancing cellular immunity towards non-B7 expressing leukemia. 23, 24 Human AML cells with 'naturally' upregulated B7 costimulatory molecule expression may possibly function in a similar way to the genetically engineered murine AML cells.
Recently, a group of investigators described culture of human CML in vitro with GM-CSF, IL-4 and TNF␣ to generate leukemic dendritic cells. 25 The cultured leukemic dendritic cells were utilized to stimulate autologous CTL that displayed cytotoxicity against uncultured CML cells. An even more recent report from the same investigators described similar findings with AML cells cultured in either GM-CSF + IL-4 + TNF␣ or CD40L. 20 The phenotype of the cytotoxic cells obtained after culture of autologous remission PBMC with the AML dendritic cells were not reported, although data were presented to suggest specificity of the cytotoxic cells for leukemia vs remission PBMC. A possible confounding aspect of the two previously mentioned reports is that both the CML and AML cells were cultured in media containing fetal bovine serum, allowing for the possibility of introduction of xenogeneic proteins and thus a xenogeneic immune response in vitro. In contrast, the culture conditions utilized in this report only included human serum, and no reagent or cells were exposed at any time to bovine or any other xenogeneic protein source. We have studied generation of autologous CTL from one of the patients in this series (patient 1) by culturing remission PBMC with either uncultured autologous AML blasts or AML blasts cultured for 5 days in GM-CSF and TNF␣. The autologous PBMC were restimulated weekly with the irradiated AML blasts with exogenous IL-2 (100 IU/ml) added after the first week. A CD4 + TCR␣␤ + cytotoxic T cell line was obtained only from the culture in which AML stimulators had been pretreated with GM-CSF + TNF␣ to upregulate CD80 expression from 0% to 55% (data not shown, manuscript in preparation).
In summary, these results demonstrate that human AML cells can be differentiated in vitro to attain a phenotype and function with some resemblance to professional APC. These cultured AML-APC could be utilized to stimulate leukemiaspecific CTL either in vitro or as a cellular vaccine. HypothetiLeukemia cally, AML cells cultured in vitro to undergo differentiation toward dendritic cell antigen presenting cells could downregulate expression of putative leukemia specific antigens. This would hamper the usefulness of this approach in the generation of leukemia-specific CTL. This possibility would need to be carefully addressed in future studies aimed at elucidating a role for cytokine cultured AML antigen presenting cells in the generation of leukemia-specific CTL.
